From Mutation to Remission: Integrating Menin Inhibitors and MRD Monitoring into Optimizing Outcomes in AML

Name: From Mutation to Remission: Integrating Menin Inhibitors and MRD Monitoring into Optimizing Outcomes in AML
Start: 2026-10-13T11:10:00-04:00
End: 2026-10-13T11:55:00-04:00
Location: Broadway South, Marriott Marquis, New York City

General Session

From Mutation to Remission: Integrating Menin Inhibitors and MRD Monitoring into Optimizing Outcomes in AML

45 min

Tuesday, October 13, 2026

11:10 AM - 11:55 AM

Supported by educational grants from Kura Oncology, Inc. and Syndax Pharmaceuticals.

Speaker
- Eytan Stein MD
- Eunice Wang MD

Room
- Broadway South